Bioprocessing & Process Optimization
Sensitively detect subtle differences in CAR-T bioprocessing methods to advance decision making1
Empower decision making in bioprocess optimization by leveraging the power of true functional T cell biology
How our Award-Winning IsoLight Single-Cell System is Making a Difference
Solution
IsoPlexis’ systems provide the complete picture
Finding
Found consistently more robust, polyfunctional response in modified CAR-T manufacturing protocol
Follow Our Data
See the latest published data in Cell Therapy
More robust polyfunctional response of CD4+ or CD8+ CAR-T cell products CD19 or CD22 with the modified manufacturing method (MM) compared to the original manufacturing method (OM).
Data demonstrates that the modified CD19/CD22 bispecific CAR-T cell manufacturing method (MM), which terminated T cell activation/transduction by culture day 3, resulted in reproducible and robust CAR-T cell production, even in the relatively more sensitive patient cells.
Solution
Detect Critical Differences
Significantly higher viable TNC, Fold Expansion, Viability, Final CD3% and Transduction Efficiency in products manufactured using the MM compared to OM. Comparable CD4/CD8 ratios across the two methods.
All products using the MM met product release criteria. In addition, final product dose requirements were consistently met by culture day 7 when using the MM, augmenting process efficiency.1
[1] Reference: Srivastava et al, ASH Annual Meeting 2018